Jaguar Animal Health (NASDAQ:JAGX) Lowered to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Jaguar Animal Health (NASDAQ:JAGX) to a strong sell rating in a research report report published on Friday.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Jaguar Animal Health in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $60.00.

Jaguar Animal Health Stock Up 4.8%

Shares of JAGX opened at $0.76 on Friday. The company’s 50-day simple moving average is $1.13 and its 200-day simple moving average is $1.74. The company has a debt-to-equity ratio of 4.08, a quick ratio of 0.52 and a current ratio of 0.81. Jaguar Animal Health has a 1 year low of $0.64 and a 1 year high of $25.75. The stock has a market capitalization of $2.86 million, a PE ratio of -0.02 and a beta of -0.42.

Jaguar Animal Health (NASDAQ:JAGX) last announced its quarterly earnings data on Friday, November 14th. The biotechnology company reported ($6.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($5.08) by ($1.20). The business had revenue of $3.08 million during the quarter, compared to analyst estimates of $3.73 million. Jaguar Animal Health had a negative net margin of 341.90% and a negative return on equity of 1,194.94%. Analysts forecast that Jaguar Animal Health will post -0.8 earnings per share for the current fiscal year.

About Jaguar Animal Health

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.